Merus (MRUS)
(Delayed Data from NSDQ)
$50.01 USD
+1.01 (2.06%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $50.02 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MRUS 50.01 +1.01(2.06%)
Will MRUS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MRUS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRUS
Should You Buy, Sell or Hold Gilead Sciences (GILD) Before Q2 Earnings?
Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates
MRUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Gilead (GILD) Loses 17.6% YTD: How Should You Play the Stock?
Other News for MRUS
Analysts Have Conflicting Sentiments on These Healthcare Companies: Merus (MRUS), Twist Bioscience (TWST) and Owens & Minor (OMI)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pennant Group (PNTG), Merus (MRUS) and Sangamo Biosciences (SGMO)
Merus to Present at Canaccord Genuity?s 44th Annual Growth Conference
3 Best Stocks to Buy Now, 8/5/2024, According to Top Analysts
Buy Rating Affirmed for Merus on Strong Clinical Progress and Capital Raise